The conundrum of B cell depletion in SLE

Nature Reviews Rheumatology

Volumn 5, Issue 6, 2009, Pages 304-305

  Sanz, Iñaki ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

B LYMPHOCYTE; CYTOLOGY; DRUG EFFECT; HUMAN; IMMUNOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68849101431     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.100     Document Type: Short Survey

References (10)

1. Phase iii study of rituxan in lupus nephritis did not meet primary endpoint [online] www.gene.com/gene/news/press-releases/display.do?method= detail&id=11947&categoryid=4 (2009).
2. Isenberg, D., Gordon, C., Merrill, J. & Urowitz, M. new therapies in systemic lupus erythematosus-trials, troubles and tribulations⋯ working towards a solution. Lupus 17, 967-970 (2008).
3. Wallace, D. new therapies in systemic lupus erythematosus-trials, troubles and tribulations-working towards a solution: part 2-the politically incorrect version. Lupus 18, 101-103 (2009).
4. Waldman, M. & Appel, G. B. Update on the treatment of lupus nephritis. Kidney Int. 70, 1403-1412 (2006).
5. Merrill, J. T. et al. efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (sLe): results from the randomized, double-blind phase ii/iii study eXPLOReR [abstract L12]. Presented at the American College of Rheumatology Annual Meeting, 2008 October 24-29, san Francisco, CA.
6. Melander, C. et al. Rituximab in severe lupus nephritis: early B-cell depletion affects longterm renal outcome. Clin. J. Am. Soc. Nephrol. 4, 579-587 (2009).
7. Anolik, J. H. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044-3056 (2007).
8. Manjarrez-Orduno, N., Quach, T. D. & sanz, I. B cells and immunological tolerance. J. Invest. Dermatol. 129, 278-288 (2009).
9. Dorner, T. & Lipsky, P. E. Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus 13, 283-289 (2004).
10. Dass, S. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58, 2993-2999 (2008).